Get the Stockscreener App
0.7746
0.69%
-0.0054
After Hours:
.78
0.0054
+0.70%
Bioaffinity Technologies Inc stock is traded at $0.7746, with a volume of 50,438.
It is down -0.69% in the last 24 hours and down -16.71% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$0.78
Open:
$0.839
24h Volume:
50,438
Relative Volume:
0.28
Market Cap:
$12.07M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-0.9563
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+22.89%
1M Performance:
-16.71%
6M Performance:
-67.59%
1Y Performance:
-51.59%
1-Day Range:
$0.7314
$0.839
1-Week Range:
$0.5951
$0.85
52-Week Range:
$0.57
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
22211 WEST INTERSTATE-10, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.7746 | 12.07M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
606.74 | 232.08B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
223.08 | 160.42B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
151.38 | 42.01B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.78 | 36.62B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
423.99 | 34.72B | 3.84B | 866.24M | 792.60M | 10.37 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies (BIAF) Stock Price, News & Analysis - MarketBeat
bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test - Mugglehead
bioAffinity secures Australian patent for lung cancer test - MSN
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic - BioSpace
bioAffinity Technologies stock hits 52-week low at $0.65 - MSN
Biotech company CEO receives pay bump - San Antonio Business Journal
bioAffinity Technologies Increases CEO Maria Zannes’ Annual Base Salary to $300,000 - Defense World
bioAffinity Technologies Adjusts CEO Compensation Package - TipRanks
bioAffinity Technologies CEO receives salary increase - Investing.com
bioAffinity Technologies (NASDAQ:BIAFW) Trading Up 4.7% – Time to Buy? - Defense World
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung - BioSpace
bioAffinity's Breakthrough Lung Cancer Test Shows 92% Accuracy, Could Save Medicare $379M - StockTitan
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
**bioAffinity Technologies Reports Results of 2024 Special Meeting** - Defense World
bioAffinity Technologies (NASDAQ:BIAF) Shares Down 2% – Here’s Why - Defense World
bioAffinity Technologies Boosts Sales with CyPath Lung - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 25.7% – Time to Sell? - Defense World
San Antonio biotech company looks to expand in 2025 - The Business Journals
bioAffinity Tech to Showcase Breakthrough Lung Cancer Detection Test in Exclusive Investor Webinar - StockTitan
Flow Cytometry in Oncology Market is Likely to Increase At - openPR
bioAffinity Technologies stock hits 52-week low at $0.91 By Investing.com - Investing.com UK
William Bauta to Spearhead Product Development at bioAffinity Technologies - MPO-mag
bioAffinity Technologies Set for Continued Expansion in 2025 - BioSpace
BioAffinity Technologies Set for Continued Expansion in 2025 - Marketscreener.com
bioAffinity's CyPath® Lung Test Drives Explosive 1,750% Sales Growth; Projects Strong 2024 Revenue - StockTitan
bioAffinity Technologies Adds Japanese Patent to its IP Portfolio - MPO-mag
bioAffinity Technologies stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule - Business Wire
bioAffinity Technologies (NASDAQ:BIAFW) Stock Price Up 24.4% – Here’s What Happened - Defense World
BioAffinity Technologies files to sell 2.72M shares of common stock for holders - Nasdaq
bioAffinity Technologies stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings roundup: Rackspace struggles as Victory Capital surges - San Antonio Express-News
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Zenopa
bioAffinity Technologies Reports Strong Q3 Growth - TipRanks
bioAffinity Technologies stock hits 52-week low at $1.24 By Investing.com - Investing.com Canada
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Zenopa
bioAffinity appoints new Chief Science Officer By Investing.com - Investing.com Canada
bioAffinity appoints new Chief Science Officer - Investing.com India
bioAffinity Technologies Appoints William Bauta, Ph.D., as Chief Science Officer - citybiz
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer - TipRanks
J. Michael Edwards Named CFO at bioAffinity Technologies - MPO-mag
SA company sets the stage for Asian expansion - The Business Journals
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):